Tocilizumab treatment in systemic juvenile idiopathic arthritis
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritisN Engl J Med. 2012 Dec 20;367(25):2385-95. doi: 10.1056/NEJMoa1112802
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
112 children, ages 2-17, suffering from active systemic juvenile idiopathic arthritis (JIA) for longer than 6 months with inadequate responses to non-steroidal anti-inflammatory drugs were included in this trial. In the first 12 week randomized double blind phase, participants were treated every 2 weeks with ether anti–interleukin-6 receptor antibody tocilizumab or with a placebo given intravenous...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue